Cytocom Inc., a biopharmaceutical company specialized in the area of immune-modulation, and Cleveland BioLabs Inc., an innovative biopharmaceutical company developing novel approaches to activate the immune system, have entered into a definitive merger agreement to combine their businesses in an all-stock transaction.   Cytocom shareholders will have a majority position in the newly combined entity, which the parties anticipate will continue to be listed on the Nasdaq, and the initial Board of D...